GLAXOSMITHKLINE $52.47

down -0.27


18/6/2013 04:18 PM  |  NYSE : GSK  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
Last Trade: 52.47
Trade Time: Jun 18 4:02 PM Eastern Daylight Time
Change: -0.27 (-0.51 %)
Prev Close: 52.74
Open: 52.37
Bid: 52.41
Ask: 52.55
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
Get Trend Analysis Icon Get GSK Trend Analysis - it has underperformed the S&P 500 by 8%

ETF Alternatives



People viewing GSK also viewed: , , , ,

Competitors

Ticker Name Volume % Change
RXEI RXELITE 45.2K +4.00%
ALSE ALSERES PHARMACEUTICALS 600.0 +1.00%
ALLP ALLIANCE PHARMACEUTICAL 3.5K +0.82%
KVPBQ K-V PHARMACEUTICAL 1.4K +0.82%
HRDN DC BRANDS INTERNATIONAL INC. C 16.7M +0.67%
View All

GSK Stock Analysis

  1. Teva to Acquire MicroDose Therapeutx - Analyst Blog

    (AZN,TEVA,GSK,BIIB )
    This deal is in line with Teva's strategy of strengthening its position in the respiratory therapeutic area.
  2.

    Sanofi's Fluzone Quadrivalent Gets FDA Nod - Analyst Blog

    (SNY,AZN,NVO,GSK )
    Sanofi announced that the FDA has cleared its quadrivalent formulation of Fluzone
  3.

    Orphan Drug Status for ViroPharma's Maribavir - Analyst Blog

    (VPHM,RHHBY,GSK,SLXP )
    ViroPharma recently received "orphan drug designation" in the EU for its pipeline candidate, maribavir, for the treatment of cytomegaloviral (CMV) in patients suffering from impaired cell mediated immunity.

  4. Dynavax Down on Heplisav Delay - Analyst Blog

    (DVAX,AZN,GSK,ANIK )
    Dynavax recently suffered a setback when the US Food and Drug Administration (FDA) asked for additional safety data on its hepatitis B vaccine candidate, Heplisav
  5.

    Glaxo Reports Disappointing Tykerb Data - Analyst Blog

    (GSK,RHHBY,SNTS,SNY )
    GlaxoSmithKline announced disappointing data from a global phase III study evaluating the use of Tykerb

  6. AstraZeneca Pays Up To Patch Up Another Key Area

    (AZN,GSK,THRX,NVS,FRX )
    In buying Pearl, AstraZeneca is taking some of the risk out of its valuable COPD franchise.
Free Reports
  1.

    Forbes Wolfe Nanotech Report Nanotech 101

    Get this Rare, First-Person Account of the Nanotechnology Industry, Absolutely Free!
  2.

    21-page Book on Learning to Trade Options on Futures!

    Not too complex. Not too basic. Just enough information to help you ask the right questions so you can start using these markets.
  3.

    Get 10 Trading Lessons FREE

    Benefit from the knowledge of MarketClub co-founder Adam Hewison and our other trading experts, with this FREE series of educational emails and online content.
Marketplace
Trading Center